CAMAPS LIBERTY
LIVE

Serial Number

79435885

Owner

CamDiab Ltd

Attorney

MICHELLE E. TOCHTROP

Filing Date

Sep 29, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CAMAPS LIBERTY Trademark

Serial Number: 79435885 • Registration: 8248843

CAMAPS LIBERTY is a trademark filed by CamDiab Ltd on September 29, 2025. The trademark is classified under Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

CamDiab Ltd (4 trademarks)

Level 4, Institute Of Metabolic Science Box 289,

Entity Type: 99

Trademark Details

Filing Date

September 29, 2025

Registration Date

May 12, 2026

Published for Opposition

March 24, 2026

Goods & Services

Downloadable computer software for providing live data regarding blood glucose readings from sensors, for remote monitoring of blood glucose readings and other signals, for alerting based on blood glucose readings, for tracking and regulating insulin delivery by insulin pump, and for the automated insulin delivery for use in the field of treatment and management of diabetes and related conditions; Downloadable mobile application software for providing live data regarding blood glucose readings from sensors, for remote monitoring of blood glucose readings and other signals, for alerting based on blood glucose readings, for tracking and regulating insulin delivery by insulin pump, and for the automated insulin delivery for use in the field of treatment and management of diabetes and related conditions; Downloadable mobile software applications for providing live data regarding blood glucose readings from sensors, for remote monitoring of blood glucose readings and other signals, for alerting based on blood glucose readings, for tracking and regulating insulin delivery by insulin pump, and for the automated insulin delivery for use in the field of treatment and management of diabetes and related conditions for use in the medical field; Downloadable computer software for providing live data regarding blood glucose readings from sensors, for remote monitoring of blood glucose readings and other signals, for alerting based on blood glucose readings, for tracking and regulating insulin delivery by insulin pump, and for the automated insulin delivery, for use with medical technology; Downloadable mobile application software for providing live data regarding blood glucose readings from sensors, for remote monitoring of blood glucose readings and other signals, for alerting based on blood glucose readings, for tracking and regulating insulin delivery by insulin pump, and for the automated insulin delivery, for use with medical technology; Downloadable computer software for calculating medicine dosages based upon medication already administered, current or predicted blood glucose levels, personal medical or physiological data, carbohydrate intake, or a combination of two or more of these factors

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 12, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 12, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Mar 19, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 18, 2026 NONP
REFUSAL PROCESSED BY IB
Mar 5, 2026 RFNT
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 4, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 3, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 25, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 24, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 24, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 24, 2026 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 13, 2026 RFCS
REFUSAL PROCESSED BY MPU
Feb 13, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 17, 2026 RFCR
NON-FINAL ACTION WRITTEN
Jan 16, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 15, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 3, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 3, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 30, 2025 REPR